<h4>Aims</h4>Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glycemic control and promote weight loss in diabetes and obesity but are also associated with gastrointestinal adverse events, including nausea and emesis in many patients. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.